For people with macular telangiectasia type 2 (MacTel), an orphan retinal disorder that gradually destroys central vision, there have long been no approved treatment options. But now, a new study sponsored by Neurotech Pharmaceuticals and spearheaded by investigators at Scripps Research and the National Institutes of Health (NIH) offers compelling evidence that vision loss can be slowed with a neuroprotective surgical implant.
Source: Medical Xpress